Abstract
Steven G. Potkin, Tatsuya Kimura and John Guarino. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Therapeutic Advances in Psychopharmacology 2045125315606027, first published on October 9, 2015. [Doi:10.1177/2045125315606027]
It has come to our attention that there were errors in Table 5, which appear to have been introduced during the conversion to SI units. Several of the values in Table 5 were not converted from mg/dL to mmol/L.
Table 5.
Changes in weight and laboratory parameters at week 6 (last observation carried forward, safety population).
| Measure | Lurasidone 20 mg/day (n = 71) |
Lurasidone 40 mg/day (n = 67) |
Lurasidone 80 mg/day (n = 71) |
Haloperidol 10 mg/day (n = 72) |
Placebo (n = 72) |
|---|---|---|---|---|---|
| Weight (kg), mean (SD) | |||||
| Baseline Change |
83.8 (20.3) -0.2 (2.6) |
87.2 (21.2) 0.0 (3.6) |
91.0 (21.5) 0.9 (4.2) |
88.4 (20.2) 0.1 (3.1) |
84.8 (22.9) 0.1 (3.0) |
| > 7% weight gain, n (%) | 1 (1.5) | 2 (3.0) | 4 (5.7) | 3 (4.3) | 2 (2.9) |
| Total cholesterol, mmol/l | |||||
| Baseline mean (SD) Median change |
5.2 (1.3) -0.3 |
5.3 (1.0) -0.5 |
5.4 (1.2) -0.3 |
5.2 (1.5) -0.2 |
5.1 (1.0) -0.3 |
| Triglycerides, mmol/l | |||||
| Baseline mean (SD) Median change |
2.1 (1.5) -0.1 |
2.0 (1.1) -0.1 |
2.3 (1.7) -0.2 |
2.1 (1.8) -0.1 |
2.0 (1.4) -0.1 |
| Glucose, mmol/l | |||||
| Baseline mean (SD) Median change |
5.7 (1.3) -0.1 |
5.3 (0.9) 0.1 |
5.7 (1.9) 0.1 |
5.4 (1.1) 0.1 |
5.5 (1.4) -0.2 |
| Prolactin, ng/ml, men | |||||
| Baseline mean (SD) Median change |
11.8 (8.2) -1.1 |
14.7 (12.0) 0.1 |
11.5 (8.9) 1.1 |
11.3 (6.3) 8.4 |
11.8 (8.3) -2.1 |
| Prolactin, ng/ml, women | |||||
| Baseline mean (SD) Median change |
13.3 (10.2) -0.7 |
23.9 (21.4) -1.3 |
15.9 (11.4) -1.0 |
22.5 (29.5) 27.6 |
21.2 (11.9) -7.9 |
SD, standard deviation.
The corrected table 5 has now been included below: